Health Economics›Cervical cancer›Persistent recurrent or metastatic disease first-line therapy

Persistent recurrent or metastatic disease first-line therapy

Cervical cancer · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Pembrolizumab Variant #03	—	R 248 201	42d	—	26.4 mo	—	—	2
Carboplatin and Paclitaxel (CP), Bevacizumab, Pembrolizumab Variant #01	—	R 112 850	21d	—	26.4 mo	—	—	2
Cisplatin and Paclitaxel (TP), Bevacizumab, Pembrolizumab Variant #01	—	R 112 074	21d	—	26.4 mo	—	—	2
Cisplatin and Paclitaxel (TP) and Pembrolizumab Variant #01	—	R 83 451	21d	—	26.4 mo	—	—	2
ABCP Variant #01	—	R 62 322	21d	13.7 mo	32.1 mo	20	R 1 246 447 PFS proxy	2
Cisplatin and Paclitaxel (TP), Atezolizumab, Bevacizumab Variant #01	—	R 61 342	21d	13.7 mo	32.1 mo	20	R 1 226 834 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #12	—	R 45 174	21d	10.4 mo	19.8 mo	16	R 722 788 PFS proxy	3
Paclitaxel, Topotecan, Bevacizumab Variant #01	—	R 33 306	21d	—	—	—	—	—
Cisplatin and Paclitaxel (TP) and Bevacizumab Variant #01	—	R 29 810	21d	10.4 mo	16.8 mo	16	R 476 954 PFS proxy	4
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	10.3 mo	—	—	1
Cisplatin and Ifosfamide Variant #01	—	R 12 083	21d	~6.0 mo	~48.0 mo	~9	~R 108 747 PFS proxy · indirect	2
Topotecan monotherapy Variant #01	—	R 11 563	21d	—	~9.0 mo	—	—	2
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	~4.0 mo	~8.4 mo	~5	~R 49 173 PFS proxy · indirect	2
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	—	17.2 mo	—	—	4
Paclitaxel and Topotecan Variant #01	—	R 4 683	21d	—	9.6 mo	—	—	—
Cisplatin and Vinorelbine (CVb) Variant #11	—	R 4 117	42d	—	10.0 mo	—	—	1
Cisplatin and Topotecan Variant #01	—	R 3 719	21d	6.0 mo	10.3 mo	9	R 33 471 PFS proxy	1
Carboplatin and Docetaxel (DCb) Variant #01	—	R 3 300	21d	~4.7 mo	~22.3 mo	~7	~R 23 101 PFS proxy · indirect	4
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	~4.7 mo	~13.1 mo	~6	~R 13 317 PFS proxy · indirect	22
Cisplatin and Mitomycin Variant #01	—	R 1 543	28d	—	—	—	—	—
Carboplatin monotherapy Variant #01	—	R 1 231	21d	~5.8 mo	~21.0 mo	~9	~R 11 076 PFS proxy · indirect	7
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	—	12.9 mo	—	—	5
Cisplatin monotherapy Variant #16	—	R 650	28d	—	19.5 mo	—	—	1
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	~9.0 mo	—	—	2

24 of 24 regimens shown